Spillover of ebolaviruses into people in eastern Democratic Republic of Congo prior to the 2018 Ebola virus disease outbreak.
Bombali virus
Eastern DRC
Ebola virus
Ebola virus disease
Ebolavirus serology
Zoonosis
Journal
One health outlook
ISSN: 2524-4655
Titre abrégé: One Health Outlook
Pays: England
ID NLM: 101769253
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
02
2020
accepted:
28
09
2020
entrez:
10
11
2020
pubmed:
11
11
2020
medline:
11
11
2020
Statut:
ppublish
Résumé
The second largest Ebola virus disease (EVD) outbreak began in the Democratic Republic of Congo in July 2018 in North Kivu Province. Data suggest the outbreak is not epidemiologically linked to the 2018 outbreak in Equateur Province, and that independent introduction of Ebola virus (EBOV) into humans occurred. We tested for antibodies to ebolaviruses in febrile patients seeking care in North Kivu Province prior to the EVD outbreak. Patients were enrolled between May 2017 and April 2018, before the declared start of the outbreak in eastern DRC. Questionnaires were administered to collect demographic and behavioural information to identify risk factors for exposure. Biological samples were evaluated for ebolavirus nucleic acid, and for antibodies to ebolaviruses. Prevalence of exposure was calculated, and demographic factors evaluated for associations with ebolavirus serostatus. Samples were collected and tested from 272 people seeking care in the Rutshuru Health Zone in North Kivu Province. All patients were negative for filoviruses by PCR. Intial screening by indirect ELISA found that 30 people were reactive to EBOV-rGP. Results were supported by detection of ebolavirus reactive linear peptides using the Serochip platform. Differential screening of all reactive serum samples against the rGP of all six ebolaviruses and Marburg virus (MARV) showed that 29 people exhibited the strongest reactivity to EBOV and one to Bombali virus (BOMV), and western blotting confirmed results. Titers ranged from 1:100 to 1:12,800. Although both sexes and all ages tested positive for antibodies, women were significantly more likely to be positive and the majority of positives were in February 2018. We provide the first documented evidence of exposure to Ebola virus in people in eastern DRC. We detected antibodies to EBOV in 10% of febrile patients seeking healthcare prior to the declaration of the 2018-2020 outbreak, suggesting early cases may have been missed or exposure ocurred without associated illness. We also report the first known detection of antibodies to BOMV, previously detected in bats in West and East Africa, and show that human exposure to BOMV has occurred. Our data suggest human exposure to ebolaviruses may be more frequent and geographically widespread.
Sections du résumé
BACKGROUND
BACKGROUND
The second largest Ebola virus disease (EVD) outbreak began in the Democratic Republic of Congo in July 2018 in North Kivu Province. Data suggest the outbreak is not epidemiologically linked to the 2018 outbreak in Equateur Province, and that independent introduction of Ebola virus (EBOV) into humans occurred. We tested for antibodies to ebolaviruses in febrile patients seeking care in North Kivu Province prior to the EVD outbreak.
METHODS
METHODS
Patients were enrolled between May 2017 and April 2018, before the declared start of the outbreak in eastern DRC. Questionnaires were administered to collect demographic and behavioural information to identify risk factors for exposure. Biological samples were evaluated for ebolavirus nucleic acid, and for antibodies to ebolaviruses. Prevalence of exposure was calculated, and demographic factors evaluated for associations with ebolavirus serostatus.
RESULTS
RESULTS
Samples were collected and tested from 272 people seeking care in the Rutshuru Health Zone in North Kivu Province. All patients were negative for filoviruses by PCR. Intial screening by indirect ELISA found that 30 people were reactive to EBOV-rGP. Results were supported by detection of ebolavirus reactive linear peptides using the Serochip platform. Differential screening of all reactive serum samples against the rGP of all six ebolaviruses and Marburg virus (MARV) showed that 29 people exhibited the strongest reactivity to EBOV and one to Bombali virus (BOMV), and western blotting confirmed results. Titers ranged from 1:100 to 1:12,800. Although both sexes and all ages tested positive for antibodies, women were significantly more likely to be positive and the majority of positives were in February 2018.
CONCLUSIONS
CONCLUSIONS
We provide the first documented evidence of exposure to Ebola virus in people in eastern DRC. We detected antibodies to EBOV in 10% of febrile patients seeking healthcare prior to the declaration of the 2018-2020 outbreak, suggesting early cases may have been missed or exposure ocurred without associated illness. We also report the first known detection of antibodies to BOMV, previously detected in bats in West and East Africa, and show that human exposure to BOMV has occurred. Our data suggest human exposure to ebolaviruses may be more frequent and geographically widespread.
Identifiants
pubmed: 33169111
doi: 10.1186/s42522-020-00028-1
pii: 28
pmc: PMC7609368
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Emerg Infect Dis. 2010 Aug;16(8):1217-23
pubmed: 20678314
J Infect Dis. 2018 Jan 4;217(2):223-231
pubmed: 29253164
Emerg Infect Dis. 2005 Feb;11(2):283-90
pubmed: 15752448
FEMS Microbiol Rev. 2016 Jul;40(4):494-519
pubmed: 27268907
J Clin Virol. 2015 Jun;67:56-8
pubmed: 25959160
Viruses. 2018 Oct 09;10(10):
pubmed: 30304789
Sci Rep. 2018 Feb 16;8(1):3158
pubmed: 29453420
mBio. 2010 Oct 12;1(4):
pubmed: 21063474
Lancet. 2011 Mar 5;377(9768):849-62
pubmed: 21084112
Virology (Auckl). 2019 Jun 21;10:1178122X19849927
pubmed: 31258326
Emerg Infect Dis. 2012 Sep;18(9):1480-3
pubmed: 22931687
PLoS One. 2015 Jun 24;10(6):e0129333
pubmed: 26107529
mBio. 2018 Mar 6;9(2):
pubmed: 29511073
Viruses. 2014 Apr 17;6(4):1759-88
pubmed: 24747773
Arch Virol. 2020 Dec;165(12):3023-3072
pubmed: 32888050
Science. 2004 Jan 16;303(5656):387-90
pubmed: 14726594
Lancet. 2015 Aug 1;386(9992):432
pubmed: 26251391
J Infect Dis. 2011 Nov;204 Suppl 3:S810-6
pubmed: 21987756
Emerg Infect Dis. 2014 Jul;20(7):1176-82
pubmed: 24959946
J Infect Dis. 2018 Jan 30;217(4):529-537
pubmed: 29329455
Philos Trans R Soc Lond B Biol Sci. 2017 May 26;372(1721):
pubmed: 28396474
Vector Borne Zoonotic Dis. 2007 Winter;7(4):467-77
pubmed: 18020965
Philos Trans R Soc Lond B Biol Sci. 2017 May 26;372(1721):
pubmed: 28396469
Lancet Infect Dis. 2019 Mar;19(3):308-316
pubmed: 30765243
EMBO Mol Med. 2014 Dec 30;7(1):17-23
pubmed: 25550396
Vector Borne Zoonotic Dis. 2009 Dec;9(6):723-8
pubmed: 19323614
Nat Rev Microbiol. 2019 May;17(5):261-263
pubmed: 30926957
PLoS Negl Trop Dis. 2019 Aug 1;13(8):e0007654
pubmed: 31369554
PLoS Pathog. 2006 Oct;2(10):e90
pubmed: 17069458
mBio. 2012 Jul 31;3(4):e00166-12
pubmed: 22851656
Lancet Infect Dis. 2017 Jun;17(6):645-653
pubmed: 28256310
Curr Top Microbiol Immunol. 2017;411:447-460
pubmed: 28653188
Sci Data. 2017 Jan 31;4:160133
pubmed: 28140390
N Engl J Med. 2018 Sep 27;379(13):1198-1201
pubmed: 30134126
Infect Dis Poverty. 2017 Oct 11;6(1):135
pubmed: 29017587
Nat Microbiol. 2018 Oct;3(10):1084-1089
pubmed: 30150734
PLoS One. 2010 Feb 09;5(2):e9126
pubmed: 20161740
J Virol. 2004 Apr;78(8):4330-41
pubmed: 15047846
Lancet Infect Dis. 2019 Sep;19(9):1023-1032
pubmed: 31300330
J Infect Dis. 2018 Nov 22;218(suppl_5):S277-S286
pubmed: 29924324
Onderstepoort J Vet Res. 2012 Jun 20;79(2):451
pubmed: 23327370
J Clin Microbiol. 2008 Aug;46(8):2652-8
pubmed: 18579717